Overview

This trial is active, not recruiting.

Conditions cancers, chronic pain
Treatment implantation of morphine sulfate delivering programmable pump
Phase phase 2/phase 3
Sponsor Medallion Therapeutics, Inc.
Start date February 2011
End date January 2015
Trial size 75 participants
Trial identifier NCT01185470, P100

Summary

• The objectives of this study are to confirm the medication delivery accuracy of the Infusion System, LLC Implantable Drug Delivery System (IDDS) with Patient Controlled Analgesia for intrathecal delivery of morphine sulfate for pain control, and to determine the safety profile of the system with PCA for intrathecal delivery of morphine sulfate for pain control.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo study device implantation .
implantation of morphine sulfate delivering programmable pump
Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo implantation of pump for intrathecal delivery of Morphine Sulfate.

Primary Outcomes

Measure
• Mean medication delivery accuracy.
time frame: 6 months

Secondary Outcomes

Measure
• Tabulation of Adverse Events
time frame: 12 months
Concomitant Medications, Physical and Neurological Exam, Inflammatory Masses, Vital Signs, Incidence of Inflammatory Masses, Summary of COWS
time frame: 6 months

Eligibility Criteria

Male or female participants at least 21 years old.

Inclusion Criteria: 1. Subject must be at least 21 years of age. 2. Subject must have experienced chronic pain for at least 6 months. 3. Subject must not presently be on intrathecal therapy but must be considered a candidate for intrathecal analgesia by his pain specialist; or, a subject already on intrathecal therapy must be in need of a replacement intrathecal pump and catheter. 4. Subject must be capable of giving informed consent. 5. Subjects who agree to sign a Pain Treatment Agreement (Narcotic Contract) limiting narcotic prescriptions to the study physician. 6. Subjects who agree to periodic drug testing. 7. Subject must be capable and willing to follow all study-related procedures, including returning for monthly refills. 8. Subject must be cognitively intact and, in the opinion of the Investigator, capable of using the Patient Remote. 9. Subject who is not already successfully treated with intrathecal analgesic therapy must be responsive to a trial of intrathecal or epidural morphine. 10. Female subjects of child-bearing potential must agree to use a medically acceptable and effective double-barrier method of birth control. 11. Documented failure to respond to less invasive methods of pain control (such as physical or behavioral modifications). 12. Ineffective pain control with single or multiple systemic analgesic treatments (oral, rectal, IV or transdermal) or had intolerable side effects. 13. Cancer pain requiring strong opioids or non-malignant pain with average Visual Analog Scale (VAS) score of ≥ 4/10. 14. Subjects who can receive an MRI. 15. Subjects must be able to hear and respond to audible alarms or agree to have a support person available who is able to hear and respond to audible alarms. Exclusion Criteria: 1. Subject is a female who is pregnant or is planning a pregnancy. 2. Subject is a nursing mother. 3. Subject has at the site chosen for implantation a skin condition that would prevent the implantation procedure. 4. Subject has participated in an investigational drug or device trial within 4 weeks prior to enrollment. 5. Subject has any known or suspected allergy to morphine or to the materials of the infusion pump or intrathecal catheter. 6. Subject shows signs of active, systemic infection. 7. Subject has a known central nervous system contraindication to intrathecal therapy, including but not limited to severe spinal canal stenosis or spinal cord compression. 8. Subject has a body size that is insufficient to accept the bulk and weight of the pump. 9. Subject is allergic to morphine sulfate, or for whom morphine sulfate is contraindicated. 10. Subject has a condition requiring diathermy procedures. 11. Subject has a life expectancy of less than 9 months. 12. Subject cannot independently comprehend and participate in the required assessments, including responding to the QOL, BPI, ODI and PGIC measurement tools. 13. Subject is not considered to be medically or psychologically appropriate for pump implantation. 14. Subject has a urine drug screen result which indicates the use of prescription drugs or controlled substances not on the order of a physician. 15. Subjects with an ASA Physical Status >IV. 16. Subjects with a history of spinal instability, or grade II spondylolisthesis or greater. 17. Previously implanted subjects with spinal MRI findings of inflammatory mass prior to the implantation procedures. 18. Subjects who are unable or unwilling to return to all of the required follow-up visits. 19. Subjects who are unwilling to sign the informed consent. 20. Subjects who are exposed to high-current industrial equipment (i.e. electricians or electrical engineers) or regularly exposed to MRI equipment (i.e. MRI technicians, MRI engineers and MRI clinicians). 21. Subjects with active implanted devices such as pacemakers, defibrillators, cochlear implants and neurostimulators or other medical device use that can interfere with the function of the implanted intrathecal pump.

Additional Information

Official title THE CLINICAL EVALUATION OF IMPLANTABLE PUMP SYSTEM FOR SAFETY AND DELIVERY ACCURACY IN PATIENTS REQUIRING INTRATHECAL ADMINISTRATION OF MORPHINE SULFATE FOR CHRONIC PAIN
Principal investigator Richard Rauck, MD
Trial information was received from ClinicalTrials.gov and was last updated in April 2015.
Information provided to ClinicalTrials.gov by Medallion Therapeutics, Inc..